Last reviewed · How we verify
Human Heterologous Liver Cells
At a glance
| Generic name | Human Heterologous Liver Cells |
|---|---|
| Sponsor | Cytonet GmbH & Co. KG |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) (PHASE1, PHASE2)
- Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients (PHASE1, PHASE2)
- Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders (PHASE2)
- Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |